S
Saraswati Sukumar
Researcher at Johns Hopkins University School of Medicine
Publications - 262
Citations - 28255
Saraswati Sukumar is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 77, co-authored 248 publications receiving 26027 citations. Previous affiliations of Saraswati Sukumar include Tufts University & Salk Institute for Biological Studies.
Papers
More filters
Journal ArticleDOI
Midkine in the progression of rat N-nitroso-N-methylurea-induced mammary tumors
TL;DR: The data suggest that loss of MK expression correlates with breast tumor progression, and raises the possibility that agents that upregulate MK could have potential in prevention and therapy by causing breast cells to terminally differentiate.
Journal ArticleDOI
Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens
Jo Heon Kim,Yoo Duk Choi,Ji Shin Lee,Jae Hyuk Lee,Jong Hee Nam,Chan Choi,Sun-Seog Kweon,Mary Jo Fackler,Saraswati Sukumar +8 more
TL;DR: Results suggest that quantitative detection of aberrant DNA methylation in cervical scrapings may be a promising high-throughput approach for the diagnosis of HSIL/SCC.
Journal ArticleDOI
Alterations in the Ha-ras-1 and the p53 pathway genes in the progression of N-methyl-N-nitrosourea-induced rat mammary tumors.
Katherine E. McKenzie,Barbara A. Armstrong,Ying Chen,Ying Chen,Mahalakshmi Nagarajan,Mahalakshmi Nagarajan,C. Marcelo Aldaz,Saraswati Sukumar +7 more
TL;DR: The p53 gene is an infrequent mutational target, and amplification of the mdm2 gene does not appear to play a role in initiation or progression of rat mammary tumorigenesis.
Book ChapterDOI
Activation of H-ras-1 oncogenes by chemical carcinogens.
TL;DR: Observations of ras oncogenes known to efficiently induce tumors in animals upon incorporation into retrovial vectors cannot be considered as sufficient evidence to establish a causal relationship between oncogene activation and the onset of human malignancies.
Journal ArticleDOI
Novel agents for chemoprevention, screening methods, and sampling issues.
TL;DR: A wide range of new breast cancer chemopreventative agents are poised to be tested in clinical trials, including those for which clinical trials have been initiated and those that are promising in the preclinical arena.